| 01/08 | PFIZER INC : Goldman Sachs gives a Neutral rating | MD |
| 2020 | PFIZER INC : RBC remains Neutral | MD |
| 2020 | PFIZER : RBC Capital Downgrades Pfizer to Sector Perform From Outperform, Adjust.. | MT |
| 2020 | PFIZER INC : Goldman Sachs gives a Neutral rating | MD |
| 2020 | PFIZER INC : Goldman Sachs remains Neutral | MD |
| 2020 | PFIZER : FDA Panel Endorses Covid-19 Vaccine -- 7th Update | DJ |
| 2020 | PFIZER : FDA Panel Endorses Covid-19 Vaccine -- 6th Update | DJ |
| 2020 | PFIZER : FDA Panel Endorses Covid-19 Vaccine -- 5th Update | DJ |
| 2020 | PFIZER : FDA Advisory Panel Endorses Pfizer-BioNTech Covid-19 Vaccine -- 3rd Upd.. | DJ |
| 2020 | WALL STREET WEEK AHEAD : After blazing energy rally, investors check the fuel ga.. | RE |
| 2020 | Barclays Adjusts Pfizer PT to $37 From $33.18, Maintains Equal Weight Rating | MT |
| 2020 | German bond yields dip before U.S. jobs data, but set for biggest weekly rise.. | RE |
| 2020 | Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 7th Update | DJ |
| 2020 | PFIZER INC : Barclays sticks Neutral | MD |
| 2020 | UK approves Pfizer-BioNTech COVID-19 vaccine in world first | RE |
| 2020 | PFIZER INC : RBC gives a Buy rating | MD |
| 2020 | PFIZER INC : Gets a Neutral rating from Goldman Sachs | MD |
| 2020 | AstraZeneca Gears Up to Vaccinate the World Against Covid-19 | DJ |
| 2020 | AstraZeneca, Oxford Covid-19 Vaccine Up to 90% Effective in Late-Stage Trials.. | DJ |
| 2020 | Rand jumps despite ratings downgrade, EM stocks rally on vaccine hopes | RE |
| 2020 | PFIZER, GILEAD, ROSS : What to Watch When the Stock Market Opens Today | DJ |
| 2020 | Goldman Resumes Pfizer at Neutral With $40 Price Target | MT |
| 2020 | MACY'S, NVIDIA, SIMON PROPERTY GROUP : What to Watch When the Stock Market Opens.. | DJ |
| 2020 | NVIDIA, SIMON PROPERTY GROUP, BNY ME : What to Watch When the Stock Market Opens.. | DJ |
| 2020 | Pfizer Says Covid Vaccine Is 95% Effective in Final Data, Will Seek Authoriza.. | DJ |
| 2020 | Pfizer's Covid-19 Vaccine 95% Effective in Final Results, Company to Seek App.. | DJ |
| 2020 | MODERNA : Rate cut bets melt as vaccines boost economy hopes | RE |
| 2020 | Aramco Plans U.S. Dollar Bond to Plug Funding Gap -- Update | DJ |
| 2020 | Bernstein Reinstates Pfizer at Market Perform with $42 Price Target | MT |
| 2020 | Arcturus expects its COVID-19 vaccine to be ready by Q1 2021 | RE |
| 2020 | PFIZER : BioNTech Shares Hit 52-Week Highs on Covid-19 Vaccine Candidate News | DJ |
| 2020 | PFIZER INC : JP Morgan reaffirms its Neutral rating | MD |
| 2020 | PFIZER INC : Barclays remains Neutral | MD |
| 2020 | PFIZER : BioNTech Shares Rise After Positive News for Covid-19 Vaccine Candidate | DJ |
| 2020 | PFIZER INC : RBC reiterates its Buy rating | MD |
| 2020 | PFIZER INC : Buy rating from RBC | MD |
| 2020 | Exxon's Departure From Dow Highlights Market's Retreat From Energy Bets | DJ |
| 2020 | Top FDA official says would resign if agency rubber-stamps an unproven COVID-.. | RE |
| 2020 | Top FDA official says would resign if agency rubber-stamps an unproven COVID-.. | RE |
| 2020 | U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive | RE |
| 2020 | Moderna shares rise 11% on $1.5 billion U.S. contract for COVID-19 vaccine | RE |
| 2020 | Biotech company CureVac aims to raise up to $245 million in U.S. IPO | RE |
| 2020 | Biotech company CureVac aims to raise up to $245 million in U.S. IPO | RE |
| 2020 | U.S. companies leap over low profit hurdle in coronavirus-hit quarter | RE |
| 2020 | U.S. companies leap over low profit hurdle in coronavirus-hit quarter | RE |
| 2020 | Pharma Companies Split on Coronavirus Vaccine Pricing Plans | DJ |
| 2020 | PFIZER INC : RBC remains its Buy rating | MD |
| 2020 | GSK's long-acting injection beats Truvada in HIV prevention trial | RE |
| 2020 | Novartis predicts rising sales and minimal disruption from coronavirus | RE |
| 2020 | PFIZER INC : JP Morgan remains Neutral | MD |
| 2020 | PFIZER INC : Gets a Buy rating from RBC | MD |
| 2019 | Bristol-Myers posts better-than-expected results, Opdivo growth slows | RE |
| 2019 | PFIZER INC : JP Morgan gives a Neutral rating | MD |
| 2019 | PFIZER INC : Upgraded to Neutral by DZ Bank | MD |
| 2019 | PFIZER INC : UBS sticks Neutral | MD |
| 2019 | PFIZER INC : JP Morgan gives a Neutral rating | MD |
| 2019 | PFIZER INC : JP Morgan reiterates its Neutral rating | MD |
| 2019 | PFIZER INC : JP Morgan reiterates its Neutral rating | MD |
| 2019 | Eliquis, Orencia sales propel Bristol-Myers to strong second quarter | RE |
| 2019 | GSK raises 2019 earnings expectations after standout quarter for Shingrix | RE |
| 2019 | GSK raises 2019 earnings expectations after standout quarter for Shingrix | RE |
| 2019 | GSK raises 2019 earnings expectations after standout quarter for Shingrix | RE |
| 2019 | PFIZER INC : JP Morgan reaffirms its Neutral rating | MD |
| 2019 | Gilead invests $5 billion to deepen ties with biotech Galapagos | RE |
| 2019 | Gilead invests $5 billion to deepen ties with biotech Galapagos | RE |
| 2019 | PFIZER INC : Receives a Buy rating from Goldman Sachs | MD |
| 2019 | PFIZER INC : Credit Suisse reiterates its Buy rating | MD |
| 2019 | PFIZER INC : JP Morgan remains Neutral | MD |
| 2019 | PFIZER INC : Credit Suisse keeps its Buy rating | MD |
| 2019 | PFIZER INC : JP Morgan sticks Neutral | MD |
| 2019 | PFIZER INC : JP Morgan reiterates its Neutral rating | MD |
| 2018 | GLOBAL MARKETS LIVE : Facebook, Pfizer, Bombardier, Nissan… | |
| 2018 | AstraZeneca sees years of growth as drug sales turn corner | RE |
| 2018 | Pfizer to replace longtime CEO Read with veteran Bourla | RE |
| 2018 | Pfizer to replace longtime CEO Read with veteran Bourla | RE |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
